Boston Ebitda vs Income Tax Expense Analysis

BSX Stock

USD 74.17 0.38 0.51%

Boston Scientific financial indicator trend analysis is way more than just evaluating Boston Scientific Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Boston Scientific Corp is a good investment. Please check the relationship between Boston Scientific Ebitda and its Income Tax Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

Ebitda vs Income Tax Expense

Ebitda vs Income Tax Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Boston Scientific Corp Ebitda account and Income Tax Expense. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Boston Scientific's Ebitda and Income Tax Expense is 0.13. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Boston Scientific Corp, assuming nothing else is changed. The correlation between historical values of Boston Scientific's Ebitda and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Boston Scientific Corp are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Ebitda i.e., Boston Scientific's Ebitda and Income Tax Expense go up and down completely randomly.

Correlation Coefficient

0.13

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Ebitda

Income Tax Expense

Most indicators from Boston Scientific's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Boston Scientific Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

At this time, Boston Scientific's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 679.4 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.29 in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	8.1B	8.7B	9.9B	10.4B
Total Revenue	11.9B	12.7B	14.2B	15.0B

Gross Profit Total Revenue

Boston Scientific fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock Total Equity	Short Term Investments
Total Assets		0.96	0.82	0.73	0.97	0.99	0.94	0.5	0.89	0.62	1.0	0.67	0.62	0.94	0.63	0.74	0.93	0.13	0.63	0.77	0.77	0.83	0.1	0.59	0.71	0.78
Short Long Term Debt Total	0.96		0.86	0.8	0.91	0.93	0.99	0.46	0.86	0.61	0.96	0.77	0.61	0.91	0.58	0.76	0.87	0.14	0.6	0.82	0.67	0.85	0.23	0.59	0.68	0.85
Other Current Liab	0.82	0.86		0.91	0.74	0.82	0.86	0.28	0.85	0.48	0.81	0.84	0.48	0.86	0.54	0.56	0.78	0.39	0.55	0.72	0.63	0.73	0.34	0.5	0.65	0.86
Total Current Liabilities	0.73	0.8	0.91		0.64	0.73	0.83	0.19	0.76	0.27	0.72	0.93	0.27	0.84	0.52	0.43	0.73	0.58	0.5	0.67	0.58	0.63	0.67	0.53	0.61	0.89
Total Stockholder Equity	0.97	0.91	0.74	0.64		0.97	0.87	0.65	0.9	0.64	0.97	0.55	0.64	0.88	0.5	0.64	0.94	0.03	0.5	0.65	0.8	0.78	0.01	0.43	0.58	0.77
Property Plant And Equipment Net	0.99	0.93	0.82	0.73	0.97		0.91	0.5	0.93	0.58	0.98	0.66	0.58	0.95	0.59	0.67	0.97	0.11	0.58	0.71	0.84	0.79	0.08	0.53	0.69	0.78
Net Debt	0.94	0.99	0.86	0.83	0.87	0.91		0.41	0.83	0.46	0.94	0.82	0.47	0.93	0.59	0.73	0.87	0.19	0.6	0.82	0.67	0.79	0.32	0.64	0.68	0.84
Retained Earnings	0.5	0.46	0.28	0.19	0.65	0.5	0.41		0.59	0.45	0.5	0.04	0.45	0.3	-0.29	0.05	0.55	-0.41	-0.23	0.05	0.56	0.3	-0.13	-0.31	-0.18	0.57
Accounts Payable	0.89	0.86	0.85	0.76	0.9	0.93	0.83	0.59		0.55	0.89	0.65	0.56	0.89	0.38	0.49	0.94	0.08	0.41	0.58	0.81	0.7	0.12	0.3	0.53	0.85
Cash	0.62	0.61	0.48	0.27	0.64	0.58	0.46	0.45	0.55		0.59	0.18	1.0	0.39	0.3	0.59	0.45	-0.13	0.43	0.54	0.29	0.78	-0.26	0.17	0.41	0.48
Non Current Assets Total	1.0	0.96	0.81	0.72	0.97	0.98	0.94	0.5	0.89	0.59		0.67	0.59	0.94	0.63	0.74	0.93	0.13	0.62	0.77	0.76	0.81	0.11	0.6	0.7	0.77
Non Currrent Assets Other	0.67	0.77	0.84	0.93	0.55	0.66	0.82	0.04	0.65	0.18	0.67		0.18	0.81	0.58	0.49	0.66	0.58	0.57	0.7	0.46	0.6	0.64	0.61	0.66	0.77
Cash And Short Term Investments	0.62	0.61	0.48	0.27	0.64	0.58	0.47	0.45	0.56	1.0	0.59	0.18		0.39	0.3	0.59	0.45	-0.13	0.43	0.54	0.29	0.78	-0.26	0.17	0.41	0.48
Net Receivables	0.94	0.91	0.86	0.84	0.88	0.95	0.93	0.3	0.89	0.39	0.94	0.81	0.39		0.69	0.67	0.94	0.29	0.65	0.76	0.78	0.73	0.27	0.67	0.77	0.77
Common Stock Shares Outstanding	0.63	0.58	0.54	0.52	0.5	0.59	0.59	-0.29	0.38	0.3	0.63	0.58	0.3	0.69		0.82	0.46	0.52	0.96	0.84	0.26	0.69	0.17	0.95	0.95	0.28
Non Current Liabilities Total	0.74	0.76	0.56	0.43	0.64	0.67	0.73	0.05	0.49	0.59	0.74	0.49	0.59	0.67	0.82		0.53	0.06	0.89	0.94	0.27	0.88	-0.04	0.83	0.86	0.38
Inventory	0.93	0.87	0.78	0.73	0.94	0.97	0.87	0.55	0.94	0.45	0.93	0.66	0.45	0.94	0.46	0.53		0.07	0.45	0.59	0.92	0.67	0.12	0.42	0.6	0.77
Other Current Assets	0.13	0.14	0.39	0.58	0.03	0.11	0.19	-0.41	0.08	-0.13	0.13	0.58	-0.13	0.29	0.52	0.06	0.07		0.42	0.28	-0.01	0.16	0.69	0.45	0.41	0.3
Other Stockholder Equity	0.63	0.6	0.55	0.5	0.5	0.58	0.6	-0.23	0.41	0.43	0.62	0.57	0.43	0.65	0.96	0.89	0.45	0.42		0.91	0.21	0.81	0.13	0.9	0.96	0.32
Total Liab	0.77	0.82	0.72	0.67	0.65	0.71	0.82	0.05	0.58	0.54	0.77	0.7	0.54	0.76	0.84	0.94	0.59	0.28	0.91		0.32	0.92	0.25	0.84	0.89	0.59
Property Plant And Equipment Gross	0.77	0.67	0.63	0.58	0.8	0.84	0.67	0.56	0.81	0.29	0.76	0.46	0.29	0.78	0.26	0.27	0.92	-0.01	0.21	0.32		0.44	0.05	0.2	0.41	0.63
Total Current Assets	0.83	0.85	0.73	0.63	0.78	0.79	0.79	0.3	0.7	0.78	0.81	0.6	0.78	0.73	0.69	0.88	0.67	0.16	0.81	0.92	0.44		0.1	0.62	0.81	0.68
Short Term Debt	0.1	0.23	0.34	0.67	0.01	0.08	0.32	-0.13	0.12	-0.26	0.11	0.64	-0.26	0.27	0.17	-0.04	0.12	0.69	0.13	0.25	0.05	0.1		0.28	0.17	0.51
Intangible Assets	0.59	0.59	0.5	0.53	0.43	0.53	0.64	-0.31	0.3	0.17	0.6	0.61	0.17	0.67	0.95	0.83	0.42	0.45	0.9	0.84	0.2	0.62	0.28		0.88	0.27
Common Stock Total Equity	0.71	0.68	0.65	0.61	0.58	0.69	0.68	-0.18	0.53	0.41	0.7	0.66	0.41	0.77	0.95	0.86	0.6	0.41	0.96	0.89	0.41	0.81	0.17	0.88		0.4
Short Term Investments	0.78	0.85	0.86	0.89	0.77	0.78	0.84	0.57	0.85	0.48	0.77	0.77	0.48	0.77	0.28	0.38	0.77	0.3	0.32	0.59	0.63	0.68	0.51	0.27	0.4

Click cells to compare fundamentals

Boston Scientific Account Relationship Matchups

Boston Scientific fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.6B	30.8B	32.2B	32.5B	35.1B	36.9B
Short Long Term Debt Total	10.3B	9.5B	9.5B	9.3B	9.5B	10.0B
Other Current Liab	2.8B	3.0B	3.0B	2.7B	3.2B	3.4B
Total Current Liabilities	4.9B	3.7B	4.3B	3.8B	4.9B	5.2B
Total Stockholder Equity	13.9B	15.3B	16.6B	17.6B	19.3B	20.2B
Property Plant And Equipment Net	2.4B	2.5B	2.7B	2.8B	3.3B	3.5B
Net Debt	10.1B	7.8B	7.5B	8.4B	8.6B	9.1B
Retained Earnings	(2.3B)	(2.4B)	(1.4B)	(750M)	819M	860.0M
Accounts Payable	542M	513M	794M	862M	942M	989.1M
Non Current Assets Total	25.9B	24.1B	25.9B	26.7B	28.6B	30.1B
Non Currrent Assets Other	735M	545M	563M	707M	679M	713.0M
Net Receivables	1.9B	1.5B	1.8B	2.0B	2.2B	2.3B
Common Stock Shares Outstanding	1.4B	1.4B	1.4B	1.4B	1.5B	1.2B
Liabilities And Stockholders Equity	30.6B	30.8B	32.2B	32.5B	34.9B	36.6B
Non Current Liabilities Total	11.8B	11.8B	11.3B	11.1B	10.7B	6.2B
Inventory	1.6B	1.4B	1.6B	1.9B	2.5B	2.6B
Other Current Assets	324M	410M	385M	350M	333M	426.3M
Other Stockholder Equity	15.8B	17.5B	17.7B	18.0B	18.4B	10.0B
Total Liab	16.7B	15.5B	15.6B	14.9B	15.6B	8.6B
Property Plant And Equipment Gross	2.4B	2.5B	2.3B	2.4B	6.8B	7.1B
Total Current Assets	4.7B	6.7B	6.3B	5.8B	6.5B	3.3B
Accumulated Other Comprehensive Income	270M	207M	263M	269M	49M	51.5M
Short Term Debt	1.4B	13M	261M	20M	531M	417.5M
Intangible Assets	7.9B	5.9B	6.1B	5.9B	6.0B	4.9B
Other Liab	3.0B	2.2B	2.1B	1.8B	2.1B	1.9B
Other Assets	(2M)	4.6B	3M	2M	(1M)	950K
Long Term Debt	8.6B	9.1B	8.8B	8.9B	8.6B	5.6B
Good Will	10.2B	10.0B	12.0B	12.9B	14.4B	8.6B
Property Plant Equipment	2.1B	2.1B	2.3B	2.8B	3.3B	1.7B
Current Deferred Revenue	144M	138M	208M	220M	266M	333.1M
Net Tangible Assets	(4.2B)	9.4B	(1.7B)	11.7B	13.4B	14.1B
Retained Earnings Total Equity	(2.3B)	(2.4B)	(1.4B)	(750M)	(862.5M)	(905.6M)
Long Term Debt Total	8.6B	9.1B	8.8B	8.9B	10.3B	6.6B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Boston Scientific Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Boston Scientific's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Boston Scientific Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Boston Scientific Corp Stock:

How To Invest In Boston

Details

Is Boston Stock a good investment?

Details

What is Boston Scientific's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Boston Stock analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.

	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon

Is Boston Scientific's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boston Scientific. If investors know Boston will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boston Scientific listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.579

Earnings Share

1.19

Revenue Per Share

10.065

Quarterly Revenue Growth

0.138

Return On Assets

0.0454

The market value of Boston Scientific Corp is measured differently than its book value, which is the value of Boston that is recorded on the company's balance sheet. Investors also form their own opinion of Boston Scientific's value that differs from its market value or its book value, called intrinsic value, which is Boston Scientific's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boston Scientific's market value can be influenced by many factors that don't directly affect Boston Scientific's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Boston Scientific's value and its price as these two are different measures arrived at by different means. Investors typically determine if Boston Scientific is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boston Scientific's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Boston Ebitda vs Income Tax Expense Analysis

Ebitda vs Income Tax Expense

Ebitda vs Income Tax Expense Correlation Analysis

Correlation Coefficient

Ebitda

Income Tax Expense

Boston Scientific fundamental ratios Correlations

Boston Scientific Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Boston Scientific fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Boston Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Net	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.97	Total Assets

Other Current Assets	- 0.41	Retained Earnings
Intangible Assets	- 0.31	Retained Earnings
Common Stock Shares Outstanding	- 0.29	Retained Earnings
Short Term Debt	- 0.26	Cash And Short Term Investments
Short Term Debt	- 0.26	Cash
Other Stockholder Equity	- 0.23	Retained Earnings